A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5386 participants.
Also called NCT07419828
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,386 participants
- Registry
-
NCT07419828
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07419828. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-13 (actual); primary completion 2030-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- HRS-1780 tablets
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct07419828- Content hash
7dfed7ba9d1df8ff561c4fb37b510f2e33e1ef57c5268aefe4d4d4c0ba6b7bee